Scott Brun

Dr. Scott Brun served in scientific & leadership roles for over 20 years at Abbott and AbbVie, two of the world’s largest biopharmaceutical companies. When AbbVie launched, Dr. Brun was selected to lead drug development, a role in which he oversaw a global organization with responsibilities for AbbVie’s entire portfolio of early and late stage clinical preregistration pipeline compounds as well as marketed compounds within oncology, neurology, immunology, renal, infectious disease, and women’s and men’s health therapeutic areas. In 2016, Dr. Brun moved from R&D to become Vice President of Scientific Affairs and Head of AbbVie Ventures, a corporate venture fund responsible for investment opportunities within the company’s current R&D therapeutic areas as well as technology platforms of interest. Dr. Brun retired from AbbVie in 2019 and is currently serving in several board, consulting, and advisory positions within the academic, VC, and biopharmaceutical industry communities.

Dr. Brun received his BS degree in Biochemistry from the University of Illinois, Urbana-Champaign, and subsequently earned an MD degree from the Johns Hopkins University School of Medicine. He completed his residency in ophthalmology at the Massachusetts Eye and Ear Infirmary/Harvard Medical School.